Gainers
- Medicines Co, Inc. MDCO shares rose 10.6% to $38.74 during Monday's pre-market session. The market cap seems to be at $2.6 billion.
- DelMar Pharmaceuticals, Inc. DMPI shares surged 7.4% to $0.82.
- Chiasma, Inc. CHMA stock increased by 6.2% to $5.50. The most recent rating by Piper Jaffray, on July 31, is at Overweight, with a price target of $11.00.
- Aptevo Therapeutics, Inc. APVO shares rose 5.0% to $0.78. The market cap seems to be at $39.9 million.
- Clearside Biomedical, Inc. CLSD shares increased by 4.4% to $0.74.
- Bristol-Myers Squibb, Inc. BMY shares rose 4.0% to $48.45. The market cap seems to be at $74.2 billion. According to the most recent rating by Atlantic Equities, on August 14, the current rating is at Overweight.
- HEXO, Inc. HEXO shares moved upwards by 3.6% to $4.15. The market cap stands at $1.0 billion. According to the most recent rating by Oppenheimer, on June 25, the current rating is at Perform.
- Celgene, Inc. CELG shares rose 3.3% to $97.10. The market cap stands at $65.8 billion.
- AVEO Pharmaceuticals, Inc. AVEO stock rose 2.8% to $0.68. The market cap stands at $571.7 million.
- Genfit, Inc. GNFT stock rose 2.6% to $17.12. The market value of their outstanding shares is at $638.7 million.
- Sangamo Therapeutics, Inc. SGMO stock rose 2.1% to $11.25.
- Invitae, Inc. NVTA stock moved upwards by 2.0% to $24.50.
- Canopy Growth, Inc. CGC stock increased by 2.0% to $25.40. The most recent rating by Seaport Global, on August 26, is at Buy, with a price target of $31.00.
Losers
- Alexion Pharmaceuticals, Inc. ALXN shares declined 2.9% to $111.99 during Monday's pre-market session. The market cap seems to be at $24.1 billion. According to the most recent rating by JP Morgan, on July 31, the current rating is at Overweight.
- Amgen, Inc. AMGN stock fell 2.6% to $193.90. The market cap seems to be at $108.8 billion. The most recent rating by Mizuho, on August 19, is at Neutral, with a price target of $212.00.
- Viveve Medical, Inc. VIVE shares declined 2.4% to $0.12. According to the most recent rating by Ladenburg Thalmann, on July 24, the current rating is at Neutral.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.